AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06256835 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation treatment
Description: Both groups are given rehabilitation treatment. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
Study NCT06256835 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Myofascial Release Therapy
Description: Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. Myofascial release therapy is commonly used to treat muscle spasms, chronic pain, skeletal and joint issues, among others.
Study NCT06360042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab plus Apatinib
Description: Adebrelimab 1200mg intravenously every 3 weeks plus Apatinib 250mg orally once daily
Study NCT06360042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab plus Bevacizumab
Description: Adebrelimab 1200mg intravenously plus Bevacizumab 15 mg/kg intravenously every 3 weeks
Study NCT06447025 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTI-1601
Description: CTI-1601 is a recombinant fusion protein and is intended to deliver human frataxin, the protein deficient in Friedreich's ataxia
Study NCT05526794 — intervention group
Intervention type: PROCEDURE
Intervention: Analgesic consumption
Description: 1 gr iv paracetamol for all patients with a VAS value of 2 or 3; for 4 and over, 1.5 mg/kg iv tramadol was administered additionally.
Study NCT04903275 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Topical fluoride application and Laser irradiation
Description: Topical fluoride varnish application (Clinpro™ White Varnish 5% Sodium Fluoride, 3M ESPE, USA) of the vestibular surfaces of the left maxillary anterior teeth followed by laser irradiation with CO2-laser (Ultra Dream Pulse, DS_40U, Daeshin Enterprise, Seoul, South Korea), emission wavelength 10,600 nm, time on-100 μs, time off-40 ms; average power-0.73 W; peak power-292.73 W; speed of movement-2 mm/s; energy density with movements-5 J/cm2; tip-to-tissue distance-20 mm; tip diameter 700 μm; irradiation time-30 s.
Study NCT04903275 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Topical fluoride application
Description: Topical fluoride varnish application (Clinpro™ White Varnish 5% Sodium Fluoride, 3M ESPE, USA) of the vestibular surfaces of the left maxillary anterior teeth
Study NCT04903444 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial intelligence assistant system
Description: The endoscopists in the experimental group will be assisted by AI system, which can instruct the direction of guide wire and the position of stent placement in real time. The system is an non-invasive AI system .
Study NCT06360042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus Apatinib
Description: camrelizumab 200mg intravenously every 2 weeks plus Apatinib 250mg orally once daily
Study NCT04709796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EmbryoGlue®, Vitrolife
Description: The intervention under study is the application of EmbryoGlue®, a class III medical device (CE Marked). EmbryoGlue® is a bicarbonate buffered medium containing recombinant human albumin, hyaluronan and gentamicin as an antibacterial agent.
Study NCT04709796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Transfer
Description: The control arm is the conventional embryo transfer without Embryo glue medium
Study NCT05026034 — intervention group
Intervention type: DEVICE
Intervention: non-invasive Cardiopulmonary Management (CPM) wearable device
Description: non-invasive Cardiopulmonary Management (CPM) wearable device with measures of congestion in heart failure
Study NCT04848649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study arm
Description: Questionnaires, blood sample, skin (for psoriasis patients) or digestive (for IBD patients) biopsy and swab testing
Study NCT04703842 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SRD-001
Description: AAV1/SERCA2a
Study NCT05775497 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Minority stress intervention
Description: The Minority Stress Intervention will teach cognitive and behavioral strategies for coping with minority stress with a focus on how minority stress impacts weight loss behaviors. The treatment will primarily address stressors due to sexuality and weight but will also cover how minority stress intersects with other facets of identity. The intervention, while innovative, is adapted from evidence-based treatments using cognitive behavioral therapy (CBT) to address minority stress.Lessons will provide psychoeducation on minority stress related to sexuality, gender, and weight, how it intersects with other aspects of identity, and how it can interfere with weight loss (e.g., unhealthy eating, avoiding exercise and healthcare, reduced motivation, disengaging from the program).The treatment will be delivered in 12 8-10-min lessons/week (a duration comparable to previous treatments) viewed directly after Rx Weight Loss lessons in Wks 1-12.
Study NCT05775497 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social support intervention
Description: The Social Support Intervention will provide sexual minority women with online opportunities to give and receive real-time social support for weight loss efforts. The treatment is based on Social Learning Theory and evidence-based online social support programs used in behavioral weight loss. The intervention will include one video lesson outlining the value of social support for weight loss and well-being, strategies for eliciting support, and an orientation to using the online platform (hosted within Rx Weight Loss). The platform will feature a private forum where participants can post to provide support and discuss their weight loss goals, challenges, and successes. To foster engagement, discussion topics will be automated to post 4 times/week and those who do not participate will be reminded via e-mail to engage (1x/month).
Study NCT05775497 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Negative body image intervention
Description: The Negative Body Image Intervention will teach CBT skills for improving negative body image and reducing its impact on weight loss behaviors. The treatment is derived from evidence-based CBT interventions targeting body image for women with obesity during behavioral weight loss and will be adapted to reflect the unique body image ideals and concerns of sexual minority women. Lessons will teach CBT strategies for coping with negative body image and reducing interference with weight loss efforts. The intervention will be delivered in 12 weekly 8-10-minute lessons, a treatment duration comparable to previous treatments and will be viewed immediately following Rx Weight Loss lessons during Weeks 1-12.
Study NCT05886049 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study NCT05886049 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration and biopsy
Study NCT05886049 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow aspiration and biopsy
Study NCT05886049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT06250127 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified 3D printed facemask
Description: modified 3D printed customized maxillary protraction facemask will be used for growing patients who have Cl. III malocclusion, hyrax expansion appliance and applying an elastic force of 300-500 gram per side for 12-14 hours per day. Treatment time 9 months.
Study NCT05886049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Given IV
Study NCT05886049 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT05886049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revumenib
Description: Given PO
Study NCT05886049 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transthoracic Echocardiography
Description: Undergo transthoracic ECHO
Study NCT06201845 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise awareness training
Description: Group exercise training will consist of aerobic exercises including warm-up and cool-down exercises accompanied by music, and trunk strengthening training consisting of core exercises.
Study NCT06201845 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical activity awareness training
Description: In the physical activity awareness training, the benefits of exercises on systemic, psychological effects and general body health will be explained and they will be informed about different exercise practice.
Study NCT06250127 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional facemask appliance
Description: Conventional facemask appliance will be used for growing patients who have Cl. III malocclusion, hyrax expansion appliance and applying an elastic force of 300-500 gram per side for 12-14 hours per day. Treatment time 9 months.
Study NCT04703842 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SRD-001 matching placebo
Study NCT06269536 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HRV biofeedback
Description: Daily deep paced breathing 3-times (minimum 7 minutes each) for 3 months
Study NCT06068777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosmary
Description: inhale two drops of rosemary oil, from a gauze, for 3 minutes before the procedure of extraction of a primary molar
Study NCT06068777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lemongrass Oil
Description: inhale two drops of lemongrass oil, from a gauze, for three minutes before the procedure of extraction.
Study NCT05453786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SID1903
Description: Single oral administration of SID1903 after an overnight fast
Study NCT05453786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SID1903-R1/SID1903-R2
Description: Single oral administration of SID1903-R1 and SID1903-R2 after an overnight fast
Study NCT05093413 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Description: Fully slept: Sleep habitual amount (i.e., go to sleep at habitual bedtime and wake up at habitual wake time) Sleep deprived: Reduce sleep by 50% (i.e., go to sleep at habitual bedtime and wake up early)
Study NCT04746079 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Imagery Therapy
Description: Perform procedural sedation with slow push of ketamine, 1.5mg/kg, over thirty seconds while reading the Positive Imagery Therapy.
Study NCT05843045 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Indoor Air Quality Mitigation
Description: Mitigation of indoor air quality with use of smart thermostat, smart bath fan control, and high quality furnace filters
Study NCT04852146 — intervention group
Intervention type: PROCEDURE
Intervention: Electronic feedback
Description: Feedbacks have been identified as one of the most effective interventions to improve practices and organisations in health care institutions. It is also a tool for facilitating and coordinating practice registers, improving the contribution of data producers and the quality of data.
Study NCT04994054 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: silkworms (Bombyx mori L.) pupae extracts group
Description: silkworms (Bombyx mori L.) pupae extracts 2,400 mg/day for 12 weeks
Study NCT04994054 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Placebo 2,400 mg/day for 12 weeks
Study NCT04683159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine Tartrate 0.15% Oph Soln
Description: 1 drop of brimonidine 0.15% (\~0.05mL) 15 minutes prior to surgery
Study NCT04683159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine Tartrate 0.025% Oph Soln
Description: 1 drop of brimonidine 0.025% (\~0.05mL) 15 minutes prior to surgery
Study NCT05309980 — intervention group
Intervention type: OTHER
Intervention: standard of care
Description: retrospective study : standard of care
Study NCT05965219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emraclidine
Description: Emraclidine tablets.
Study NCT05965219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole oral solution.
Study NCT05965219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Description: Carbamazepine tablets.
Study NCT05965219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin tablets.
Study NCT05045703 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin A palmitate
Description: Vitamin A palmitate, 15,000 IU daily for 4 months
Study NCT05565391 — intervention group
Intervention type: DRUG
Intervention: Elranatamab
Description: BCMA-CD3 bispecific antibody
Study NCT05565391 — intervention group
Intervention type: DRUG
Intervention: Standard of care
Description: Standard of care
Study NCT05437341 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bi-4SCAR PSMA/CD70 T cells
Description: Infusion of bi-4SCAR PSMA/CD70 T cells at 10\^6 cells/kg body weight via IV
Study NCT06142461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gardasil
Description: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant Pre-filled syringe, 0.5mL dose volume
Study NCT06142461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gardasil
Description: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant Needle-free intramuscular injection, 0.5mL dose volume
Study NCT06142461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gardasil
Description: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant Needle-free intradermal injection, 0.2mL dose volume
Study NCT06142461 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PharmaJet Stratis® Needle-Free Injection System
Description: 0.5mL dose injection
Study NCT06142461 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PharmaJet Tropis® Needle-Free Injection System
Description: 0.1mL dose injection
Study NCT05873517 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate Narrative Exposure Therapy (NET)+
Description: The basis of this intervention is adapted Narrative Exposure Therapy (NET)+. All participants receive 4-8 active NET+ sessions, including a psychoeducational session.
Study NCT05873517 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist + NET+
Description: Waitlist control group participants receive 1 psychoeducational sessions and will be added to a waitlist; waitlist control group participants randomly selected from the waitlist be offered the opportunity to receive the active intervention (NET+).
Study NCT04872582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 Immune Checkpoint Inhibitor Combined With Bevacizumab
Description: combined
Study NCT05112458 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cope 360 mobile health application
Description: Cope 360 is a mHealth (mobile health) app designed to support caregivers of children with cancer with symptom tracking, medication management, and emergency preparedness. We will evaluate Cope 360 via a pilot, randomized control trial in which some caregivers will receive the app and some will not. The purpose of this study is to assess: 1) feasibility of caregiver use over extended period of time, 2) acceptability of the mHealth tool by caregivers in a real-world setting, 3) impact of the mHealth tool on caregiver self-efficacy, mastery of caregiving skills/knowledge, and caregiver stress, and 4) effect on healthcare utilization of the child with cancer (i.e. preliminary data about sick visits and ED encounters).
Study NCT05112458 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Caregivers of children with cancer will receive the usual clinical care provided to our patient population.
Study NCT06376214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dratumumab / Hyaluronidase Injection [Darzalex Faspro]
Description: Daratumumab will be administered at the FDA-approved dose of 16mg/kg as an intravenous infusion.
Study NCT06376214 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dratumumab / Hyaluronidase Injection [Darzalex Faspro]
Description: Daratumumab will be administered at the FDA-approved dose of 16mg/kg as an intravenous infusion.
Study NCT06376214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide 4 MG
Description: Patients received oral pomalidomide on days 1-21 of a 28-days cycle from cycle 1 to 6.
Study NCT04851730 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orthopedic Physical Therapy Intervention
Description: First, a deep slow breathing protocol is intended to increase the expansion of the pelvic floor, utilizing the relationship between the diaphragm and the pelvic floor, resulting in a gentle stretching of the pelvic floor.~Next, abdominal soft tissue mobilization, or scar mobilization of the lumbopelvic abdominal area will take place.~Next, manual therapy to the thoracic or lumbar spine or the hips will be performed based on the impairments found in the orthopedic evaluation.~The participant will be given a home exercise program to support breath training, and manual therapy. During the initiation of the second visit each participant will watch a standardized pain education video on the tablet, Understanding pain in less than 5 minutes and what to do about it The above plan of care will be completed 2 times/week for 4 weeks for a total of 8 visits.
Study NCT04851730 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: Third, the investigator will dry needle appropriate muscles. Dry needling treatment technique will include insertion of a sterile, disposable, solid filament needle into the muscle belly in the area palpated as listed below. A 0.30 × 0.50mm, or specified size below, stainless steel Seirin J-type or Myotech needle will be used (Dommerholt 2011). Clean technique will be employed throughout the treatment procedure which includes hand washing, clean latex-free glove use, and skin-surface preparation with an alcohol swab ( Baima \& Isaac 2008). Each muscle will receive a maximal number of 2 insertions and each insertion consists of up to 5 seconds of a pistoning (in and out motion) technique in an attempt to elicit a local twitch response. Standard protocol for each muscle will be established prior to beginning data collection.~Details about the dry needling protocol can be found in Appendix L.
Study NCT04844333 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extubation under deep anesthesia
Description: When the patient in sedation or anesthesia state, no body movement, bispectral index 60-70, spontaneous breathing recovery, VT ≥ 5ml / kg, respiratory rate 10-20 times / min, regular rhythm, PetCO2 \< 45mmhg, regular waveform, stable circulation, the patient is in deep anesthesia state, and the endotracheal tube is removed.
Study NCT05214235 — intervention group
Intervention type: DRUG
Intervention: Hypoglycemic Drugs
Description: Patients were divided into metformin group and sitagliptin group according to the type of hypoglycemic drugs they took.
Study NCT06437314 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aquatic program based on the back school
Description: Participants will undertake a back school-based program. This program will follow the recommendations of the biopsychosocial model of chronic pain and will be conducted in an aquatic environment. The intervention will be carried out by physiotherapists in a sports center. The duration of the intervention will be six weeks, with a frequency of two sessions per week, totaling 12 sessions of 45 minutes each. Of all the sessions, 10 will have a practical focus (centered on trunk exercises) and the other two will have a theoretical focus (providing education on pain and risk factors for low back pain).
Study NCT05672745 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WB-LIFE
Description: WB-LIFE is a mobile application program grounded in validated psychotherapies (including cognitive behavioral therapy, interpersonal, and dialectical behavioral therapy), that enlists the relational agent Woebot to guide users in managing their mood. The user experience is driven by artificial intelligence and centers around mood tracking, evidence-based tools, and goal-oriented, tailored conversations.
Study NCT05189678 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT06428396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belzutifan
Description: Belzutifan 120 mg administered QD as an oral tablet.